BioNTech (NASDAQ:BNTX) Price Target Cut to $106.00 by Analysts at Morgan Stanley

BioNTech (NASDAQ:BNTX) had its price target reduced by Morgan Stanley from $114.00 to $106.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have an overweight rating on the stock.

BNTX has been the subject of several other research reports. UBS Group reaffirmed a “buy” rating on shares of BioNTech in a research report on Wednesday, September 16th. Bank of America reissued a “buy” rating on shares of BioNTech in a research report on Wednesday. BMO Capital Markets lowered shares of BioNTech from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $128.00 to $105.00 in a report on Tuesday, September 8th. Canaccord Genuity Group reduced their target price on BioNTech from $136.00 to $132.00 and set a “buy” rating for the company in a research note on Wednesday, October 14th. Finally, Citigroup decreased their price target on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $123.60.

BioNTech Stock Up 4.3%

BNTX opened at $90.70 on Wednesday. BioNTech has a 52 week low of $79.52 and a 52 week high of $124.00. The firm has a market cap of $22.94 billion, a P/E ratio of -13.24 and a beta of 1.28. The business’s fifty day simple moving average is $95.68 and its 200 day simple moving average is $96.91. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. BioNTech had a negative return on equity of 4.45% and a negative net margin of 61.39%. The business’s quarterly revenue was down 59.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.60) earnings per share. As a group, equities research analysts anticipate that BioNTech will post -6.62 EPS for the current fiscal year.

Insider Transactions at BioNTech

In related news, CEO Ugur Sahin sold 36,209 shares of the firm’s stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $95.37, for a total transaction of $3,453,252.33. Following the completion of the sale, the chief executive officer directly owned 36,209 shares in the company, valued at approximately $3,453,252.33. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 807,209 shares of company stock valued at $79,246,837. 19.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On BioNTech

A number of large investors have recently bought and sold shares of BNTX. Headlands Technologies LLC bought a new position in BioNTech in the 2nd quarter worth approximately $2,520,000. Bank of America Corp DE lifted its holdings in shares of BioNTech by 22.6% during the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after acquiring an additional 166,432 shares during the period. Amundi boosted its holdings in BioNTech by 24.5% during the first quarter. Amundi now owns 129,513 shares of the company’s stock valued at $11,511,000 after purchasing an additional 25,506 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in BioNTech by 79.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 760,675 shares of the company’s stock valued at $74,774,000 after buying an additional 337,412 shares in the last quarter. Finally, Flossbach Von Storch SE acquired a new stake in shares of BioNTech in the 2nd quarter valued at $207,142,000. 15.52% of the stock is currently owned by institutional investors.

BioNTech News Roundup

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Q3 results topped expectations: BioNTech reported EPS of $1.99 versus the $0.76 consensus and revenue of €1.29 billion (about $1.49 billion), ahead of estimates. The company also raised its 2026 revenue guidance midpoint, projecting €1.7–€1.9 billion for the year. Article: BioNTech beats third-quarter forecasts and raises revenue guidance despite pipeline setbacks
• Positive Sentiment: Oncology progress offered potential catalysts: The company highlighted data for pumitamig combinations and reported that gotistobart nearly doubled median overall survival versus chemotherapy in previously treated squamous non-small cell lung cancer. An interim gotistobart analysis is expected before year-end. Article: BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
• Neutral Sentiment: Analysts trimmed targets but kept favorable ratings: UBS cut its target to $125 from $135, Morgan Stanley to $106 from $114, and Wells Fargo to $125 from $140. All maintained Buy or Overweight ratings, suggesting they still see upside from the recent share price. UBS Group recommendations
• Negative Sentiment: Revenue and pipeline risks remain: Q3 revenue fell 15.1% year over year amid lower COVID-19 vaccine demand. A bearish analysis also flagged ongoing cash burn, declining liquid assets and reliance on a narrower oncology pipeline centered on pumitamig and gotistobart. Article: BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet

BioNTech Company Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing medicines and vaccines based on messenger RNA and other immunotherapy technologies. The company’s research programs address cancer, infectious diseases, and other serious medical conditions.

BioNTech’s oncology portfolio includes individualized and off-the-shelf cancer immunotherapies, including mRNA-based treatments, cell therapies, antibody-based therapies, and immune-modulating approaches. Its infectious-disease activities include vaccine programs developed through proprietary platforms and collaborations.

In collaboration with Pfizer, BioNTech developed Comirnaty, an mRNA-based COVID-19 vaccine.